• Troels Jordansen is an international and experienced cell and gene therapy leader with past roles covering commercial, general management, and board responsibilities

KELI Therapeutics appoints experienced cell and gene therapy leader Troels Jordansen as Executive Chair of the Board

1st August 2024, Kaunas, Lithuania

KELI Therapeutics is researching and delivering innovative treatments for highly unmet medical needs. We develop and manufacture cellular therapies and have extracellular vesicle therapeutic production in our own Good Manufacturing Practice facility for impaired immunology and inflammatory conditions.

Dr. Justinas Maciulaitis, CEO and Founder of Keli Therapeutics, said, “We are launching our cartilage repair and osteoarthritis cell-based products in late 2024. We are hopefully will be able to start our clinical trial for post-cardiac surgery Acute Kidney Injury early in 2025. On this background, we wanted to strengthen our company with a person who has experience in these activities to help us reach our objectives as fast and cost-effective as possible. Having screened the market for talent, we feel fortunate to have met Troels Jordansen, and we are looking forward to a long and successful collaboration.”

Troels Jordansen said, “It is a great honor to be joining KELI Therapeutics at this stage of the company’s development. I am positively surprised how much has already been done in such a short time at KELI Therapeutics, but when I consider the people working at KELI Therapeutics, I sense the urgency and interest in transforming the lives of patients around the world.”

About KELI Therapeutics

Funded in 2019, KELI Therapeutics already has many publications (please review here) covering cartilage regeneration and mesenchymal stromal cell research. In 2025, this will result in KELI Therapeutics providing clinical services out of Lithuania and initiating clinical trial activities for a highly unmet medical need - acute Kidney Injury - and a pipeline of inflammatory disorders.

Utilizing the stomal stem cells from the perinatal tissues and by taking advantage of the effective and proprietary manufacturing methods for the high yields of potent cell and EV. Further proprietary processing will ensure highly potent products benefiting patients worldwide. Strategically co-located with the largest Central European Health Sciences University and Hospital, KELI Therapeutics thrives in a dynamic ecosystem of research, development, and commercialization. This prime location fosters diverse collaborations and accelerates our mission to bring cutting-edge treatments to market.

For further information, please contact Dr. Justinas Maciulaitis, founder and CEO, at +370 690 22777 or info@keli.eu. Visit our website at www.keli.eu to learn more about our work

• In collaboration with management teams, Troels has raised more than $200 million in equity and more than $500 million in deal value

• Troels will join KELI Therapeutics with a focus on securing a financial platform for clinical activities in large kidney and knee joint indications